Abstract | OBJECTIVE: BACKGROUND:
COPD is a progressive lung disease that is characterized by persistent airflow limitation and is a major contributor to the disease burden in China. Symptoms in Chinese patients are relatively more severe. Currently, many Chinese COPD patients are undertreated. Dual bronchodilator therapy consisting of a long-acting muscarinic antagonist (LAMA) and a long-acting β agonist (LABA) is considered a good choice for COPD patients due to the increased bronchodilation without an increase in adverse events; these combinations can fill in the gap in currently available COPD treatments and provide new pharmacotherapy options for Chinese patients. LAMA/LABA fixed-dose combinations (FDCs) have become more important in clinical practice and guidelines in China regarding their therapeutic effects and safety. METHODS: Clinical trials on LAMA/LABA in COPD were retrieved in ClinicalTrials.gov, while important COPD guidelines published in English or Chinese were found in PubMed and Wanfang Database. CONCLUSIONS: We recommend the adoption of a clinical pathway in China that includes an assessment and management algorithm that considers the clinical characteristics in China and classifies the phenotypic characteristics of COPD according to a suitable system. Based on the current information, we can conclude that LAMA/LABA FDCs are a suitable and economically viable choice to reduce symptoms and improve the quality of life (QoL) of patients.
|
Authors | Ji'an Zhou, Jing Zhang, Min Zhou, Jingqing Hang, Min Zhang, Fengfeng Han, Huili Zhu |
Journal | Journal of thoracic disease
(J Thorac Dis)
Vol. 13
Issue 11
Pg. 6453-6467
(Nov 2021)
ISSN: 2072-1439 [Print] China |
PMID | 34992824
(Publication Type: Journal Article, Review)
|
Copyright | 2021 Journal of Thoracic Disease. All rights reserved. |